The estimated Net Worth of Robert Coffin is at least 40.7 百万$ dollars as of 16 May 2024. Dr Coffin owns over 11,464 units of Replimune Inc stock worth over 18,892,813$ and over the last 6 years he sold REPL stock worth over 21,061,393$. In addition, he makes 759,525$ as Founder、 Pres、 Chief R&D Officer and Director at Replimune Inc.
Dr has made over 14 trades of the Replimune Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 11,464 units of REPL stock worth 74,172$ on 16 May 2024.
The largest trade he's ever made was selling 220,000 units of Replimune Inc stock on 22 December 2020 worth over 8,808,800$. On average, Dr trades about 36,918 units every 85 days since 2018. As of 16 May 2024 he still owns at least 1,821,872 units of Replimune Inc stock.
You can see the complete history of Dr Coffin stock trades at the bottom of the page.
Dr. Robert Coffin Ph.D. is the Founder, Pres, Chief R&D Officer and Director at Replimune Inc.
As the Founder、 Pres、 Chief R&D Officer and Director of Replimune Inc, the total compensation of Dr D at Replimune Inc is 759,525$. There are 2 executives at Replimune Inc getting paid more, with Pradeep Misra having the highest compensation of 7,920,000$.
Dr D is 56, he's been the Founder、 Pres、 Chief R&D Officer and Director of Replimune Inc since . There are 2 older and 6 younger executives at Replimune Inc. The oldest executive at Replimune Group Inc is Dr. Colin A. Love Ph.D., 63, who is the Chief Operating Officer.
Robert's mailing address filed with the SEC is C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, SUITE 303, WOBURN, MA, 01801.
Over the last 6 years, insiders at Replimune Inc have traded over 72,652,546$ worth of Replimune Inc stock and bought 2,360,000 units worth 33,565,200$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Capital Life Sciences Inves...、Jason P Rhodes. On average, Replimune Inc executives and independent directors trade stock every 21 days with the average trade being worth of 508,649$. The most recent stock trade was executed by Emily Luisa Hill on 16 August 2024, trading 8,938 units of REPL stock currently worth 90,989$.
replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.
Replimune Inc executives and other stock owners filed with the SEC include: